Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Faye Lanni"'
Autor:
Sarah K. Cooper, David Forrest Ackart, Faye Lanni, Marcela Henao-Tamayo, G. Brooke Anderson, Brendan K. Podell
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
The control of bacterial growth is key to the prevention and treatment of tuberculosis (TB). Granulomas represent independent foci of the host immune response that present heterogeneous capacity for control of bacterial growth. At the whole tissue le
Externí odkaz:
https://doaj.org/article/d3abf1a56ca54c45854449446b7414b0
Autor:
Andrew D. White, Andy C. Tran, Laura Sibley, Charlotte Sarfas, Alexandra L. Morrison, Steve Lawrence, Mike Dennis, Simon Clark, Sirine Zadi, Faye Lanni, Emma Rayner, Alastair Copland, Peter Hart, Gil Reynolds Diogo, Matthew J. Paul, Miyoung Kim, Fergus Gleeson, Francisco J. Salguero, Mahavir Singh, Matthias Stehr, Simon M. Cutting, Juan I. Basile, Martin E. Rottenberg, Ann Williams, Sally A. Sharpe, Rajko Reljic
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Tuberculosis remains a major health threat globally and a more effective vaccine than the current Bacillus Calmette Guerin (BCG) is required, either to replace or boost it. The Spore-FP1 mucosal vaccine candidate is based on the fusion protein of Ag8
Externí odkaz:
https://doaj.org/article/5d6971450abd4bfbb64716fb58efad30
Autor:
Laura Sibley, Andrew D. White, Charlotte Sarfas, Jennie Gullick, Fergus Gleeson, Faye Lanni, Simon Clark, Emma Rayner, Santiago Ferrer-Bazaga, Fatima Ortega-Muro, Laura Alameda, Joaquin Rullas, Veronica Sousa, Marisa Martinez, Inigo Angulo-Barturen, Adolfo Garcia, Juan José Vaquero, Henry E. Pertinez, Geraint Davies, Mike Dennis, Ann Williams, Sally Sharpe
Publikováno v:
Pharmaceutics, Vol 14, Iss 12, p 2666 (2022)
Innovative cross-over study designs were explored in non-human primate (NHP) studies to determine the value of this approach for the evaluation of drug efficacy against tuberculosis (TB). Firstly, the pharmacokinetics (PK) of each of the drugs Isonia
Externí odkaz:
https://doaj.org/article/de04d1d2aadf4dc2bc3352fe889680e3
Autor:
Faye Lanni, Neil Burton, Debbie Harris, Susan Fotheringham, Simon Clark, Oliver Skinner, Nathan Wiblin, Mike Dennis, Stuart Armstrong, Geraint Davies, Ann Williams
Publikováno v:
PLoS ONE, Vol 16, Iss 1, p e0245922 (2021)
Optimised pre-clinical models are required for TB drug development to better predict the pharmacokinetics of anti-tuberculosis (anti-TB) drugs to shorten the time taken for novel drugs and combinations to be approved for clinical trial. Microdialysis
Externí odkaz:
https://doaj.org/article/5a42857d8f764b6a978d11917ae9ff78
Publikováno v:
Tuberculosis. 139:102318
Autor:
Firat Kaya, Jacqueline P. Ernest, Katherine LoMauro, Martin Gengenbacher, Abdeldjalil Madani, Wassihun Wedajo Aragaw, Matthew D. Zimmerman, Jansy P. Sarathy, Nadine Alvarez, Isaac Daudelin, Han Wang, Faye Lanni, Danielle M. Weiner, Laura E. Via, Clifton E. Barry, Kenneth N. Olivier, Thomas Dick, Brendan K. Podell, Radojka M. Savic, Véronique Dartois
Publikováno v:
Antimicrob Agents Chemother
Antimicrobial agents and chemotherapy, vol 66, iss 3
Antimicrobial agents and chemotherapy, vol 66, iss 3
Nontuberculous mycobacterial pulmonary disease (NTM-PD) is a potentially fatal infectious disease requiring long treatment duration with multiple antibiotics and against which there is no reliable cure. Among the factors that have hampered the develo
Autor:
Bhagwati Khatri, Mei Mei Ho, Michael J. Brennan, Simon Clark, Megan Fitzpatrick, Belinda Dagg, Barry Walker, Ann Williams, Dominick Laddy, Faye Lanni
Publikováno v:
Tuberculosis. 114:47-53
A global BCG vaccine shortage began in 2013 which impacted availability for infant vaccinations, as well as preclinical studies and clinical trials of new TB vaccines. Stakeholders met in 2015 at McGill University in Montreal to discuss the shortage
Autor:
Stuart J. Armstrong, Mike Dennis, Geraint Davies, Faye Lanni, Susan A. Fotheringham, Debbie J Harris, Simon Clark, Ann Williams, Neil K Burton, Oliver Skinner, Nathan R Wiblin
Publikováno v:
PLoS ONE, Vol 16, Iss 1, p e0245922 (2021)
PLoS ONE
PLoS ONE
Optimised pre-clinical models are required for TB drug development to better predict the pharmacokinetics of anti-tuberculosis (anti-TB) drugs to shorten the time taken for novel drugs and combinations to be approved for clinical trial. Microdialysis
Autor:
Neil McLeod, Faye Lanni, Graham R. Stewart, Sirine Zadi, Neeraj Bharti, Ann Williams, Ruma Banerjee, Aneesh Chandran, Bernado Villarreal-Ramos, Veerasamy Maroudam, Aravind Prasad, Kerstin Williams, Sunitha Manjari Kasibhatla, Johnjoe McFadden, Simon Clark, Martin Vordermeier, Tom A. Mendum
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-1 (2020)
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Autor:
Priscille Brodin, Christophe Guilhot, Simon Clark, Sung Jae Shin, Olivier Neyrolles, Florence Levillain, Felipe Cia, Wladimir Malaga, Gregory J. Bancroft, Hongmin Kim, Yannick Poquet, Ann Williams, Brigitte Gicquel, Kee Woong Kwon, Faye Lanni
Publikováno v:
Vaccine
Vaccine, Elsevier, 2020, 38 (6), pp.1416-1423. ⟨10.1016/j.vaccine.2019.11.085⟩
Vaccine, Elsevier, 2020, 38 (6), pp.1416-1423. ⟨10.1016/j.vaccine.2019.11.085⟩
Tuberculosis still claims more lives than any other pathogen, and a vaccine better than BCG is urgently needed. One of the challenges for novel TB vaccines is to protect against all Mycobacterium tuberculosis lineages, including the most virulent one
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5e7ab780b4eb596c571468448cda351
https://hal.archives-ouvertes.fr/hal-03014488
https://hal.archives-ouvertes.fr/hal-03014488